THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG FOR ADVANCED MDS OR AML AND SEVERE THROMBOCYTOPENIA: 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 ASPIRE STUDY

被引：0
|
作者：
Mittelman, M. [1 ]
Platzbecker, U. [2 ]
Afanasyev, B. [3 ]
Grosicki, S. [4 ]
Wong, R. S. [5 ,6 ]
Anagnostopoulos, A. [7 ]
Brenner, B. [8 ]
Denzlinger, C. [9 ]
Rossi, G. [10 ]
Nagler, A. [11 ]
Garcia Delgado, R. [12 ]
Stone, N. [13 ]
Zhu, Z. [13 ]
Kalambakas, S. [13 ]
Selleslag, D. [14 ]
机构：
[1] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[2] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[3] Pavlov State Med Univ, St Petersburg, Russia
[4] Silesian Med Univ, Katowice, Poland
[5] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China
[6] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[7] G Papanikolaou Gen Hosp, Thessaloniki, Greece
[8] Rambam Med Ctr, Haifa, Israel
[9] Marienhosp Stuttgart, Stuttgart, Germany
[10] Azienda Osped Spedali Civili, Brescia, Italy
[11] Chaim Sheba Med Ctr, Ramat Gan, Israel
[12] Hosp Virgen de la Victoria, Malaga, Spain
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] AZ St Jan Brugge AV, Brugge, Belgium
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S130
引用
收藏
页码：15 / 16
页数：2
相关论文
共 50 条
  • [1] Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial
    Mittelman, Moshe
    Platzbecker, Uwe
    Afanasyev, Boris
    Grosicki, Sebastian
    Wong, Raymond S. M.
    Anagnostopoulos, Achilles
    Brenner, Benjamin
    Denzlinger, Claudio
    Rossi, Giuseppe
    Nagler, Arnon
    Garcia-Delgado, Regina
    Portella, Maria Socorro O.
    Zhu, Zewen
    Selleslag, Dominik
    LANCET HAEMATOLOGY, 2018, 5 (01): : 34 - 43
  • [2] Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Combination with Azacitidine (AZA) for Primary Treatment of Myelodysplastic Syndromes (MDS) Patients with Thrombocytopenia: Outcomes from the Randomized, Placebo-Controlled, Phase III Support Study
    Dickinson, Michael J.
    Cherif, Honor
    Fenaux, Pierre
    Mittleman, Moshe
    Verma, Amit
    Portella, Maria Socorro O.
    Burgess, Paul
    Platzbecker, Uwe
    BLOOD, 2016, 128 (22)
  • [3] RANDOMIZED, PLACEBO (PBO)-CONTROLLED, PHASE I/II TRIAL OF THE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG (EPAG) IN THROMBOCYTOPENIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS)
    Platzbecker, U.
    Wong, R. S.
    Araujo, S.
    Feigert, J.
    Bennett, J.
    Messam, C.
    Mannino, F.
    Kamel, Y. Mostafa
    Dougherty, S.
    Chan, G.
    Giagounidis, A.
    HAEMATOLOGICA, 2015, 100 : 67 - 68
  • [4] PLACEBO-CONTROLLED, RANDOMIZED, PHASE I/II TRIAL OF THE THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG IN THROMBOCYTOPENIC PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES OR ACUTE MYELOID LEUKEMIA
    Platzbecker, U.
    Wong, R.
    Verma, A.
    Abboud, C.
    Araujo, S.
    Chiou, T.
    Feigert, J.
    Yeh, S.
    Goetze, K.
    Gorin, N.
    Greenberg, P.
    Kambhampati, S.
    Kim, Y.
    Lee, J.
    Lyons, R.
    Ruggeri, M.
    Santini, V.
    Cheng, G.
    Jang, J.
    Chen, C.
    Dougherty, S.
    Mannino, F.
    Kamel, Y.
    Chan, G.
    Arning, M.
    Stone, N.
    Giagounidis, A.
    HAEMATOLOGICA, 2013, 98 : 455 - 455
  • [5] Risperidone for severe tardive dyskinesia: A 12-week randomized, double-blind, placebo-controlled study
    Bai, YM
    Yu, SC
    Lin, CC
    JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (11) : 1342 - 1348
  • [6] Efficacy and Safety of a Selective Estrogen Receptor β Agonist, ERB-041, in Patients With Rheumatoid Arthritis: A 12-Week, Randomized, Placebo-Controlled, Phase II Study
    Roman-Blas, Jorge A.
    Castaneda, Santos
    Cutolo, Maurizio
    Herrero-Beaumont, Gabriel
    ARTHRITIS CARE & RESEARCH, 2010, 62 (11) : 1588 - 1593
  • [7] Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
    Eric S. Winer
    Howard Safran
    Boguslawa Karaszewska
    Sebastian Bauer
    Dilawar Khan
    Steffen Doerfel
    Paul Burgess
    Stacey Kalambakas
    Yasser Mostafa Kamel
    Frederic Forget
    International Journal of Hematology, 2017, 106 : 765 - 776
  • [8] ELTROMBOPAG IN COMBINATION WITH AZACITIDINE FOR FIRST-LINE TREATMENT OF MDS PATIENTS WITH THROMBOCYTOPENIA: THE RANDOMIZED, PLACEBO-CONTROLLED, PHASE III, SUPPORT STUDY
    Dickinson, M.
    Cherif, H.
    Fenaux, P.
    Mittelman, M.
    Verma, A.
    Portella, M. S. O.
    Burgess, P.
    Platzbecker, U.
    LEUKEMIA RESEARCH, 2017, 55 : S23 - S24
  • [9] Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study
    Winer, Eric S.
    Safran, Howard
    Karaszewska, Boguslawa
    Bauer, Sebastian
    Khan, Dilawar
    Doerfel, Steffen
    Burgess, Paul
    Kalambakas, Stacey
    Kamel, Yasser Mostafa
    Forget, Frederic
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (06) : 765 - 776
  • [10] Phase 3, Placebo-Controlled, ASPIRE Study (TRC1 14968) of Eltrombopag (EPAG) Treatment of Thrombocytopenia (TCP) in Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Assessment of Clinical Benefit, Safety, and Tolerability
    Mittelman, Moshe
    Platzbecker, Uwe
    Afanasyev, Boris V.
    Grosicki, Sebastian
    Wong, Raymond S. M.
    Anagnostopoulos, Achilles
    Brenner, Benjamin
    Denzlinger, Claudio
    Rossi, Giuseppe
    Nagler, Arnon
    Mas, Ana Isabel Rosell
    Mannino, Frank
    Stone, Nicole L.
    Chan, Geoffrey
    Kamel, Yasser Mostafa
    Selleslag, Dominik L. D.
    BLOOD, 2015, 126 (23)
12345